AR079092A1 - Flavonas sustituidas por pirrolidina como radio sensibilizadores - Google Patents
Flavonas sustituidas por pirrolidina como radio sensibilizadoresInfo
- Publication number
- AR079092A1 AR079092A1 ARP100101501A ARP100101501A AR079092A1 AR 079092 A1 AR079092 A1 AR 079092A1 AR P100101501 A ARP100101501 A AR P100101501A AR P100101501 A ARP100101501 A AR P100101501A AR 079092 A1 AR079092 A1 AR 079092A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- treatment
- cancer
- formula
- cdk
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente se relaciona con una combinacion para el tratamiento del cáncer en donde la combinacion exhibe un efecto sinergístico. La combinacion comprende la radiacion y por lo menos un inhibidor de quinasa dependiente de ciclina (CDK) seleccionado de los compuestos de la formula 1 o una sal o un solvato farmacéuticamente aceptable de los mismos. La presente también se relaciona con un método para el tratamiento del cáncer, método que comprende la administracion del mencionado tratamiento a un paciente que lo necesite, de una cantidad terapéuticamente efectiva de la combinacion. La presente también se relaciona con el uso de un inhibidor CDK seleccionado de los compuestos de la formula 1 como un radiosensibilizador que aumenta la eficacia de la radioterapia para el tratamiento del cáncer, especialmente el cáncer de cabeza y de cuello. Reivindicacion 1: Una combinacion que comprende la radiacion y un inhibidor CDK o una sal o un solvato farmacéuticamente aceptable de los mismos, en donde el mencionado inhibidor CDK está representado por la formula (1); en donde Ar es fenilo, que se encuentra no sustituido o sustituido por 1, 2, o 3 sustituyentes idénticos o diferentes seleccionados de: halogeno seleccionado de cloro, bromo, fluor o yodo; nitro, ciano, alquilo C1-4, trifluorometilo, hidroxilo, alcoxi C1-4, carboxi, alcoxicarbonilo C1-4, CONH2, y NR1R2; en donde R1 y R2 se seleccionan independientemente de hidrogeno o alquilo C1-4.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1174MU2009 | 2009-05-05 | ||
| US22452409P | 2009-07-10 | 2009-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079092A1 true AR079092A1 (es) | 2011-12-28 |
Family
ID=42352216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101501A AR079092A1 (es) | 2009-05-05 | 2010-05-04 | Flavonas sustituidas por pirrolidina como radio sensibilizadores |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8895605B2 (es) |
| EP (1) | EP2427188B1 (es) |
| JP (1) | JP5730288B2 (es) |
| KR (1) | KR20120032476A (es) |
| CN (1) | CN102458398B (es) |
| AR (1) | AR079092A1 (es) |
| AU (1) | AU2010244101A1 (es) |
| CA (1) | CA2761182A1 (es) |
| IL (1) | IL216163A0 (es) |
| MX (1) | MX2011011687A (es) |
| NZ (1) | NZ596861A (es) |
| RU (1) | RU2011148954A (es) |
| TW (1) | TWI461194B (es) |
| WO (1) | WO2010128443A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201242597A (en) * | 2011-03-14 | 2012-11-01 | Piramal Life Sciences Ltd | A synergistic pharmaceutical combination for the treatment of pancreatic cancer |
| TW201300105A (zh) * | 2011-05-31 | 2013-01-01 | Piramal Life Sciences Ltd | 治療頭頸鱗狀細胞癌之相乘藥物組合物 |
| MX2013014950A (es) | 2011-06-24 | 2014-04-16 | Piramal Entpr Ltd | Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. |
| WO2013105056A1 (en) * | 2012-01-13 | 2013-07-18 | Piramal Enterprises Limited | Pyrrolidine- substituted flavone derivatives for prevention or treatment of oral mucositis |
| CA3163776A1 (en) | 2012-08-03 | 2014-02-06 | Foundation Medicine, Inc. | Human papilloma virus as predictor of cancer prognosis |
| TWI680760B (zh) | 2013-07-12 | 2020-01-01 | 印度商皮拉馬爾企業有限公司 | 治療黑色素瘤的藥物組合 |
| CN114478524A (zh) * | 2022-03-15 | 2022-05-13 | 江苏省肿瘤医院 | 1,8-萘啶类化合物及其应用 |
| CN114560799A (zh) * | 2022-03-15 | 2022-05-31 | 江苏省肿瘤医院 | 腈基取代苯基类化合物及其应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN164232B (es) | 1986-04-11 | 1989-02-04 | Hoechst India | |
| US6281223B1 (en) * | 1999-04-13 | 2001-08-28 | Supergen, Inc. | Radioenhanced camptothecin derivative cancer treatments |
| TWI331034B (en) | 2002-07-08 | 2010-10-01 | Piramal Life Sciences Ltd | Inhibitors of cyclin-dependent kinases and their use |
| US7272193B2 (en) | 2003-06-30 | 2007-09-18 | Intel Corporation | Re-mapping trellis encoded data associated with a 2-bit constellation tone to data associated with a pair of 1-bit constellation tones |
| DK2046738T3 (da) * | 2006-06-21 | 2014-08-04 | Piramal Entpr Ltd | Enantiomerisk rene flavonderivativer til behandlingen af proliferative lidelser, samt processer til deres tilberedelse |
| PT2041121E (pt) | 2006-07-07 | 2011-09-12 | Piramal Life Sciences Ltd | Síntese enantiosselectiva de pirrolidinas substituídas com flavonas |
| WO2008139271A2 (en) | 2007-05-15 | 2008-11-20 | Piramal Life Sciences Limited | A synergistic pharmaceutical combination for the treatment of cancer |
-
2010
- 2010-04-19 TW TW099112188A patent/TWI461194B/zh not_active IP Right Cessation
- 2010-05-03 AU AU2010244101A patent/AU2010244101A1/en not_active Abandoned
- 2010-05-03 NZ NZ596861A patent/NZ596861A/en unknown
- 2010-05-03 MX MX2011011687A patent/MX2011011687A/es active IP Right Grant
- 2010-05-03 CA CA2761182A patent/CA2761182A1/en not_active Abandoned
- 2010-05-03 CN CN201080027763.5A patent/CN102458398B/zh active Active
- 2010-05-03 KR KR1020117029101A patent/KR20120032476A/ko not_active Application Discontinuation
- 2010-05-03 US US13/318,235 patent/US8895605B2/en active Active
- 2010-05-03 WO PCT/IB2010/051921 patent/WO2010128443A1/en active Application Filing
- 2010-05-03 RU RU2011148954/15A patent/RU2011148954A/ru unknown
- 2010-05-03 EP EP10724898.1A patent/EP2427188B1/en active Active
- 2010-05-03 JP JP2012509135A patent/JP5730288B2/ja active Active
- 2010-05-04 AR ARP100101501A patent/AR079092A1/es not_active Application Discontinuation
-
2011
- 2011-11-06 IL IL216163A patent/IL216163A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US8895605B2 (en) | 2014-11-25 |
| IL216163A0 (en) | 2012-01-31 |
| WO2010128443A1 (en) | 2010-11-11 |
| RU2011148954A (ru) | 2013-06-10 |
| JP2012526098A (ja) | 2012-10-25 |
| EP2427188A1 (en) | 2012-03-14 |
| NZ596861A (en) | 2014-01-31 |
| CA2761182A1 (en) | 2010-11-11 |
| EP2427188B1 (en) | 2016-08-10 |
| KR20120032476A (ko) | 2012-04-05 |
| AU2010244101A1 (en) | 2012-01-12 |
| AU2010244101A2 (en) | 2011-12-22 |
| TW201039817A (en) | 2010-11-16 |
| US20120046334A1 (en) | 2012-02-23 |
| CN102458398B (zh) | 2014-07-16 |
| JP5730288B2 (ja) | 2015-06-10 |
| CN102458398A (zh) | 2012-05-16 |
| MX2011011687A (es) | 2012-02-29 |
| TWI461194B (zh) | 2014-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079092A1 (es) | Flavonas sustituidas por pirrolidina como radio sensibilizadores | |
| ECSP19044159A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| SV2018005663A (es) | Compuestos de imidazo [4,5-c] quinolin-2-ona y su uso en el tratamiento del cancer | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| SV2011004077A (es) | Derivados aminobutiricos sustituidos como inhibidores de neprilisina | |
| CL2011002990A1 (es) | Compuestos derivados de bifenilo, inhibidores de endopeptidasa neutra (nep); composición farmacéutica; combinación farmacéutica; uso del compuesto para tratar un trastorno o enfermedad tal como la hipertensión, insuficiencia cardiaca, insuficiencia renal, glaucoma, trastornos reproductivos, entre otros. | |
| SV2018005680A (es) | Compuestos de imidazo [4,5-c] quinolin- 2-ona y su uso en el tratamiento del cancer | |
| ECSP066653A (es) | Derivados de bencenosulfonilamino-piridin-2-il y compuestos relacionados como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1(ii-beta-hsd-1) para el tratamiento de la diabetes y de la obesidad | |
| CL2020002562A1 (es) | (divisional de solicitud 1097-2020) derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| MX2019003143A (es) | Compuesto heterociclico sustituido con alquinilo, su metodo de preparacion y su uso medico. | |
| AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
| EA201270570A1 (ru) | Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90 | |
| ECSP11011136A (es) | Compuestos útiles para inhibir chk1 | |
| AR090712A1 (es) | Agentes para tratar trastornos que implican la modulacion de receptores de rianodina | |
| RU2013127655A (ru) | Фармацевтическая комбинация паклитаксела и ингибитора cdk | |
| ECSP14007965A (es) | Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetil aminoisoindolin-1, 3-diona | |
| ECSP088179A (es) | Compuestos de carbamato para usarse en el tratamiento de desordenes neurodegenerativos | |
| CO6361924A2 (es) | Nuevas lactamas como inhibidores de beta secretasa | |
| AR076300A1 (es) | Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades. | |
| CL2022001337A1 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| CL2020002605A1 (es) | Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer. | |
| CO2020013834A2 (es) | Ciertos compuestos de pladienolida y métodos de uso | |
| AR128500A1 (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| CL2022001741A1 (es) | Compuestos cíclicos y métodos de uso de estos | |
| UY31775A (es) | Compuestos heterocíclicos como inhibidores de mek |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |